Chang Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Chang Yu has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Haofeng Pan
Division of Pulmonary Medicine, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou Key Laboratory of Interdiscipline and Translational Medicine, Wenzhou Key Laboratory of Heart and Lung, Wenzhou, Zhejiang 325000, China
2 shared publicationsJun Chen
Division of Pulmonary Medicine, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou Key Laboratory of Interdiscipline and Translational Medicine, Wenzhou Key Laboratory of Heart and Lung, Wenzhou, Zhejiang 325000, China
2 shared publications- Xiaoying Huang
Key Laboratory of Heart and Lung, Division of Pulmonary Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
2 shared publications Yuxin Chen
Wenzhou Medical University, Wenzhou, Zhejiang 325000, China
2 shared publicationsZhanghang Lv
Division of Pulmonary Medicine, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou Key Laboratory of Interdiscipline and Translational Medicine, Wenzhou Key Laboratory of Heart and Lung, Wenzhou, Zhejiang 325000, China
2 shared publicationsZiyi Lu
Division of Pulmonary Medicine, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou Key Laboratory of Interdiscipline and Translational Medicine, Wenzhou Key Laboratory of Heart and Lung, Wenzhou, Zhejiang 325000, China
2 shared publications
Latest Publications
- Open Access
- 25 January 2025
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 208, 114650
Hexahistidine-metal assembly encapsulated fibroblast growth factor 21 for lipopolysaccharide-induced acute lung injury
- 25 January 2025
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 208, 114650
Open AccessHexahistidine-metal assembly encapsulated fibroblast growth factor 21 for lipopolysaccharide-induced acute lung injury
- Open Access
- 15 April 2024
- Published by Elsevier in Life Sciences
- Vol. 346, 122648
Icariside II alleviates lipopolysaccharide-induced acute lung injury by inhibiting lung epithelial inflammatory and immune responses mediated by neutrophil extracellular traps
- 15 April 2024
- Published by Elsevier in Life Sciences
- Vol. 346, 122648
Open AccessIcariside II alleviates lipopolysaccharide-induced acute lung injury by inhibiting lung epithelial inflammatory and immune responses mediated by neutrophil extracellular traps